Kenota System revolutionizes the allergy testing experience for patients and clinicians. It puts lab-quality IgE testing capability directly into allergists’ offices, giving them additional information they can use to quickly and accurately diagnose allergies in a single visit.
In the U.S. alone, more than 32 million people suffer from food allergies — a number that’s only growing. Many allergies are life threatening, and there is no cure. Testing is crucial to determine their presence, severity and treatment. But until now, the available testing options have had drawbacks for both patients and clinicians.
Kenota is decentralizing allergy testing with a proprietary approach that employs rapid, point of care instrumentation. Capable of swiftly quantifying a patient’s sensitization to allergens, our system is compact, streamlined and can be administered easily by allergists and their staff.
Designed with allergists in mind
Uncovers sensitizations with a few drops of blood
Easy to administer: results and reports generated on the spot
Allergists can provide end-to-end care in a single visit – no need for lab referrals
From the outset, we’ve had an unwavering vision: to change allergy testing to deliver a better system for allergists and a better experience to patients. Here are some highlights of our journey so far:
Developed concept for in-clinic allergy testing system
Established scalable 33,000 square-foot manufacturing facility in Waterloo Region, Canada
Created pilot systems and conducted successful allergy clinic pilot study
Raised $11 million in Series A funding
Kenota submits technology to FDA
Kenota Health is pleased to announce that the FDA has accepted a Dual Track (Dual 510(k) and CLIA Waiver by Application) submission for their new device, the Kenota 1 System and Kenota 1 Total IgE assay. The system, with its first assay (total IgE), has been designed to bring quantitative IgE testing to the allergy clinic without the need for a full CLIA laboratory license. Click here to read more.
Kenota has added US diagnostic business leaders Ruth Abdulmassih and Dennis Flannelly to its board of directors. Both bring extensive experience that will help guide Kenota as it advances toward complete development and clearance of its product. “The addition of Dennis and Ruth to the Kenota board is a significant step forward for our company,” stated Kenota CEO and Founder, Moufeed Kaddoura. Click here to read more.
In this virtual summit, Moufeed Kaddoura, founder and CEO of Kenota will join other leading early stage and emerging growth innovators as they present live to top investors.
Kenota’s founder and CEO to present at the 2021 Emerging Medtech Summit, which brings together “the most innovative medtech startups, active investors and strategic buyers to deal-make and collaborate about the future of our industry.”
Kenota has raised $11 million in funding to provide rapid, reliable, point of care allergy testing. An initial seed round of $2 million in 2016 was used to begin validating our approach with physicians, followed by a Series A of $9 million, led by leading global venture fund, Draper Associates — the first institutional investor to back Tesla, Benchling, Robinhood, Skype, Hotmail and more than 20 other unicorns. Click here for article.
Tune in to hear Kenota founder and CEO Moufeed Kaddoura’s interview with Zoomcast — a podcast featuring entrepreneurs and professionals — about the company’s journey from founding to funding.
Kenota Health is an entrepreneurially minded team with deep scientific, clinical and commercial expertise. An idea first sparked in the tech hotbed of Waterloo Region has grown into a team of passionate and innovative professionals, collectively focused on elevating healthcare through the world’s best data and testing technology.